June 5, 2008 Arno Therapeutics Completes $30.7 Million Financing, Recapitalization and 1-for-8 Reverse Stock Split
January 28, 2008 Arno Therapeutics Initiates Pharmacokinetic Study for Onapristone Following Regulatory Acceptance – Biotrial to Serve as Contract Research Organization for Paris-Based Trial
January 28, 2008 Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds
